Endostatin is a new targeted therapeutic agent, which can inhibit the proliferation of vascular endothelium, induce the apoptosis of endothelial cells, block the signaling pathway of vascular endothelial growth factor (VEGF) and down-regulate the expression of genes related to angiogenesis to play an anti-tumor role.[6] In 2005, the State Food and Drug Administration of China approved the application of the modified recombinant human endostatin endostar for the treatment of NSCLC. Here, VEGFA is linked to non-small cell lung carcinoma.